Investigation of Nonneoplastic Neurologic Disorders with PET and MRI.
暂无分享,去创建一个
[1] D E Kuhl,et al. Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F]fluorodeoxyglucose method , 1984, Annals of neurology.
[2] P. Scheltens,et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.
[3] C. Patlak,et al. Nigrostriatal function in humans studied with positron emission tomography , 1989, Annals of neurology.
[4] David Eidelberg,et al. Metabolic correlates of subthalamic nucleus activity in Parkinson's disease. , 2008, Brain : a journal of neurology.
[5] R. Duncan. Epilepsy, cerebral blood flow, and cerebral metabolic rate. , 1992, Cerebrovascular and brain metabolism reviews.
[6] J. Constantinidis,et al. Pick’s Disease , 1974 .
[7] PET imaging in Parkinsonism. , 1993 .
[8] R. Worth,et al. Comparative study of interictal PET and ictal SPECT in complex partial seizures , 1997, Acta neurologica Scandinavica.
[9] H. Ruottinen,et al. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease. , 2001, Synapse.
[10] L F Quesney,et al. False lateralization by surface EEG of seizure onset in patients with temporal lobe epilepsy and gross focal cerebral lesions , 1987, Annals of neurology.
[11] Scott T. Grafton,et al. A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease , 1990, Annals of neurology.
[12] J. Pruim,et al. Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease , 2005, Neurology.
[13] Paul Maruff,et al. β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .
[14] H. Engler,et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.
[15] Richard S. J. Frackowiak,et al. The identification of presymptomatic parkinsonism: Clinical and {18F}dopa positron emission tomography studies in an irish kindred , 1992, Annals of neurology.
[16] Paul Edison,et al. Amyloid load and cerebral atrophy in Alzheimer's disease: An 11C‐PIB positron emission tomography study , 2006, Annals of neurology.
[17] M. Viitanen,et al. Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease , 2008, Annals of neurology.
[18] Nelleke Tolboom,et al. Simplified parametric methods for [11C]PIB studies , 2008, NeuroImage.
[19] M. Viitanen,et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment , 2007, Neurology.
[20] C. Markham,et al. Cerebral metabolism and atrophy in huntington's disease determined by 18FDG and computed tomographic scan , 1982, Annals of neurology.
[21] K. Gwinn‐Hardy,et al. The role of radiotracer imaging in Parkinson disease , 2005, Neurology.
[22] Robert M. Kessler,et al. Imaging methods for evaluating brain function in man , 2003, Neurobiology of Aging.
[23] H. Rusinek,et al. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer’s disease , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[24] H. Engler,et al. PET imaging of amyloid deposition in patients with mild cognitive impairment , 2008, Neurobiology of Aging.
[25] C D Marsden,et al. Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography , 1986, Movement disorders : official journal of the Movement Disorder Society.
[26] R Harrop,et al. Positron emission tomography and histopathology in Pick's disease , 1987, Neurology.
[27] G. Small,et al. Binding Characteristics of Radiofluorinated 6-Dialkylamino-2-Naphthylethylidene Derivatives as Positron Emission Tomography Imaging Probes for β-Amyloid Plaques in Alzheimer's Disease , 2001, The Journal of Neuroscience.
[28] W. Jagust,et al. Longitudinal studies of regional cerebral metabolism in Alzheimer's disease , 1988, Neurology.
[29] Naokazu Miyamoto,et al. Comparison of grey matter and metabolic reductions in frontotemporal dementia using FDG-PET and voxel-based morphometric MR studies , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[30] P. Crandall,et al. Comparative localization of epileptic foci in partial epilepsy by PCT and EEG. , 1982, Annals of neurology.
[31] W. Jagust,et al. Reduced Temporal Lobe Glucose Metabolism in Aging , 1995, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[32] Henry Rusinek,et al. Quantitation, regional vulnerability, and kinetic modeling of brain glucose metabolism in mild Alzheimer’s disease , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[33] A J Lees,et al. Familial progressive supranuclear palsy: detection of subclinical cases using 18F-dopa and 18fluorodeoxyglucose positron emission tomography. , 2001, Archives of neurology.
[34] A. Alavi,et al. Studies of central nervous system disorders with single photon emission computed tomography and positron emission tomography: evolution over the past 2 decades. , 1991, Seminars in nuclear medicine.
[35] P. Maquet,et al. Contribution of positron emission tomography to the investigation of epilepsies of frontal lobe origin. , 1992, Advances in neurology.
[36] Dong Young Lee,et al. Topographic Patterns of Brain Functional Impairment Progression According to Clinical Severity Staging in 116 Alzheimer Disease Patients: FDG-PET Study , 2007, Alzheimer disease and associated disorders.
[37] C. Markham,et al. Patterns of cerebral glucose utilization in Parkinson's disease and Huntington's disease , 1984, Annals of neurology.
[38] L. Mansi,et al. CORTICAL ABNORMALITIES IN ALZHEIMER'S DISEASE , 1984, Annals of neurology.
[39] Michael Channing,et al. {18F}fluorodeoxyglucose positron emission tomography in refractory complex partial seizures , 1983, Annals of neurology.
[40] R S Frackowiak,et al. Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status. , 1993, Brain : a journal of neurology.
[41] I Lemahieu,et al. Cerebral oxygen metabolism in patients with progressive supranuclear palsy: a positron emission tomography study. , 1997, European neurology.
[42] U Ruotsalainen,et al. PET study on striatal dopamine D2 receptor changes during the progression of early parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.
[43] A. Alavi. Functional and anatomic studies of head injury. , 1989, The Journal of neuropsychiatry and clinical neurosciences.
[44] C. Rowe,et al. Imaging β-amyloid burden in aging and dementia , 2007, Neurology.
[45] Hans Clusmann,et al. THE SURGERY OF EPILEPSY , 2008, Neurosurgery.
[46] Controlling for Cerebral Atrophy in Positron Emission Tomography Data , 1987, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[47] A. Lang,et al. Striatal dopamine distribution in Parkinsonian patients during life , 1985, Journal of the Neurological Sciences.
[48] I. Fried,et al. Pick's Disease: A Clinical, Computed Tomographic, and Histologic Study With Golgi Impregnation Observations , 1982 .
[49] B. Choe,et al. Cerebral glucose metabolism in corticobasal degeneration comparison with progressive supranuclear palsy using statistical mapping analysis , 2005, Neuroscience Letters.
[50] Hiroyuki Okada,et al. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: A double‐tracer positron emission tomography study , 1999, Annals of neurology.
[51] K. Lindahl-Kiessling,et al. USE AND ABUSE OF ELECTROENCEPHALOGRAPHY. , 1964, Lancet.
[52] Richard S. J. Frackowiak,et al. The use of positron emission tomography in the clinical assessment of dementia. , 1992, Seminars in nuclear medicine.
[53] C. DeCarli,et al. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? , 2007, Neurology.
[54] T. Rasmussen,et al. Histopathology of nonneoplastic lesions in frontal lobe epilepsy. Review of 180 cases with recent MRI and PET correlations. , 1992, Advances in neurology.
[55] D Comar,et al. Differential diagnosis of Alzheimer's disease with PET. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[56] B. Levin,et al. Predominant left hemisphere metabolic dysfunction in dementia. , 1989, Archives of neurology.
[57] A. Alavi,et al. A Metabolic Imaging Severity Rating Scale for the Assessment of Cognitive Impairment , 2003, Clinical nuclear medicine.
[58] M E Phelps,et al. Patterns of human local cerebral glucose metabolism during epileptic seizures. , 1982, Science.
[59] B. Choe,et al. Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET. , 2004, European journal of radiology.
[60] Cesar C. Santos,et al. 18‐FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY IN CHILDREN AND ADOLESCENTS WITH TRAUMATIC BRAIN INJURY , 1995 .
[61] M. Raichle,et al. [18F]-labeled 3-deoxy-3-fluoro-D-glucose: synthesis and preliminary biodistribution data. , 1978, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[62] S. Folstein,et al. D2 receptors in Huntington's disease: positron emission tomography findings and clinical correlates. , 1990, The Journal of neuropsychiatry and clinical neurosciences.
[63] Jane S. Paulsen,et al. Thalamic metabolism and symptom onset in preclinical Huntington's disease. , 2007, Brain : a journal of neurology.
[64] V. Dhawan,et al. Network modulation in the treatment of Parkinson's disease. , 2006, Brain : a journal of neurology.
[65] M. Phelps,et al. Dissociation of cerebral glucose metabolism and level of consciousness during the period of metabolic depression following human traumatic brain injury. , 2000, Journal of neurotrauma.
[66] H. Fukuyama,et al. Atrophy of the corpus callosum, cognitive impairment, and cortical hypometabolism in progressive supranuclear palsy , 1997, Annals of neurology.
[67] M. Mendez,et al. Accuracy of the clinical evaluation for frontotemporal dementia. , 2007, Archives of neurology.
[68] H. Herzog,et al. Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. , 1990, Brain : a journal of neurology.
[69] Michael E. Phelps,et al. Comparative localization of foci in partial epilepsy by PCT and EEG , 1982 .
[70] J. Mazziotta,et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. , 1987, The New England journal of medicine.
[71] H. Kung. Overview of radiopharmaceuticals for diagnosis of central nervous disorders. , 1991, Critical reviews in clinical laboratory sciences.
[72] D Comar,et al. Local cerebral glucose utilisation in treated and untreated patients with Parkinson's disease. , 1984, Journal of neurology, neurosurgery, and psychiatry.
[73] Andrew Newberg,et al. Neuroimaging of traumatic brain injury. , 2008, Seminars in neurology.
[74] G. Alexander,et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.
[75] B Horwitz,et al. Relation of measured brain glucose utilisation and cerebral atrophy in man. , 1987, Journal of neurology, neurosurgery, and psychiatry.
[76] 保坂 加代. Voxel-based comparison of regional cerebral glucose metabolism between PSP and corticobasal degeneration , 2003 .
[77] R Harrop,et al. Comparison of PET, MRI, and CT with pathology in a proven case of Alzheimer's disease , 1986, Neurology.
[78] D. Brooks,et al. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease , 1996, Annals of neurology.
[79] Sébastien Ourselin,et al. Appearance modeling of 11C PiB PET images: Characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging , 2008, NeuroImage.
[80] K. Leenders,et al. Long‐term changes of striatal dopamine D2 Receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]Raclopride , 1997, Movement disorders : official journal of the Movement Disorder Society.
[81] Y Agid,et al. Subcortical dementia. Frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy. , 1985, Brain : a journal of neurology.
[82] Lisa A. Weissfeld,et al. Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease , 2006, NeuroImage.
[83] C. Marsden. BASAL GANGLIA DISEASE , 1982, The Lancet.
[84] W. Theodore,et al. Patterns of cerebral glucose metabolism in patients with partial seizures , 1988, Neurology.
[85] Takayuki Kato,et al. Statistical image analysis of cerebral glucose metabolism in patients with cognitive impairment following diffuse traumatic brain injury. , 2007, Journal of neurotrauma.
[86] E. Hoffman,et al. TOMOGRAPHIC MEASUREMENT OF LOCAL CEREBRAL GLUCOSE METABOLIC RATE IN HUMANS WITH (F‐18)2‐FLUORO-2‐DEOXY-D‐GLUCOSE: VALIDATION OF METHOD , 1980, Annals of neurology.
[87] P. Van Bogaert,et al. Statistical Parametric Mapping of Regional Glucose Metabolism in Mesial Temporal Lobe Epilepsy , 2000, NeuroImage.
[88] J. Haxby,et al. Anatomic, metabolic, neuropsychological, and molecular genetic studies of three pairs of identical twins discordant for dementia of the Alzheimer's type. , 1991, Archives of neurology.
[89] D. Eidelberg,et al. Abnormal metabolic networks in atypical parkinsonism , 2008, Movement disorders : official journal of the Movement Disorder Society.
[90] Conrad V. Kufta,et al. Temporal lobectomy for uncontrolled seizures: The role of positron emission tomography , 1992, Annals of neurology.
[91] W. Jagust,et al. Regional cerebral glucose transport and utilization in Alzheimer's disease , 1989, Neurology.
[92] P. Mcgeer,et al. Cortical glucose metabolism in parkinson's and alzheimer's disease , 1990, Journal of neuroscience research.
[93] C. Rowe,et al. The ART of Loss: Aβ Imaging in the Evaluation of Alzheimer’s Disease and other Dementias , 2008, Molecular Neurobiology.
[94] Nir Giladi,et al. Positron emission tomography in hemiparkinsonism-hemiatrophy syndrome. , 1993, Advances in neurology.
[95] Sanjiv S. Gambhir,et al. Positron Emission Tomography in Evaluation of Dementia , 2001 .
[96] S. Gilman,et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging , 1996, Annals of neurology.
[97] Matthias Reimold,et al. [11C]PIB binding in Parkinson's disease dementia , 2008, NeuroImage.
[98] R. Grossman,et al. MR imaging of Parkinson disease with spin-echo and gradient-echo sequences. , 1988, AJR. American journal of roentgenology.
[99] T. Vogt,et al. The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[100] A. Alavi,et al. Quantitative analysis of PET and MRI data in normal aging and Alzheimer's disease: atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[101] C. Rowe,et al. Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism , 2008, The Lancet Neurology.
[102] G. Alexander,et al. Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment. , 2008, Archives of neurology.
[103] M. Seller. SCREENING FOR NEURAL-TUBE DEFECTS , 1975, The Lancet.
[104] J. Haxby,et al. Relations between Neuropsychological and Cerebral Metabolic Asymmetries in Early Alzheimer's Disease , 1985, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[105] Keith A. Johnson,et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. , 2007, Archives of neurology.
[106] W. Snow,et al. The NINCDS‐ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease , 1988, Neurology.
[107] J. Haxby,et al. Clinical history, brain metabolism, and neuropsychological function in Alzheimer's disease , 1985, Annals of neurology.
[108] J. Baron,et al. Mild cognitive impairment , 2003, Neurology.
[109] G. Sedvall,et al. IN-VIVO DEMONSTRATION OF REDUCED BENZODIAZEPINE RECEPTOR BINDING IN HUMAN EPILEPTIC FOCI , 1988, The Lancet.
[110] Schwartz,et al. Neuroimaging in Closed Head Injury. , 1997, Seminars in Clinical Neuropsychiatry.
[111] R. Frackowiak. PET: Studies in dementia , 1989, Psychiatry Research.
[112] Luigi Mansi,et al. Regional cortical dysfunction in Alzheimer's disease as determined by positron emission tomography , 1984, Annals of neurology.
[113] M. Reivich,et al. Cognitive, neuroimaging, and pathological studies in a patient with Pick's disease , 1998, Annals of neurology.
[114] Characterization of dopaminergic dysfunction in familial progressive supranuclear palsy: an 18F-dopa PET study , 2007, Journal of Neural Transmission.
[115] H. Fukuyama,et al. Cerebral glucose metabolism in corticobasal degeneration: Comparison with progressive supranuclear palsy and normal controls , 1997, Movement disorders : official journal of the Movement Disorder Society.
[116] M. Sasaki,et al. Differentiating between multiple system atrophy and Parkinson’s disease by positron emission tomography with18F-dopa and18F-FDG , 1997, Annals of nuclear medicine.
[117] M. D. de Leon,et al. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[118] Vesna Sossi,et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. , 2005, Brain : a journal of neurology.
[119] H. Engler,et al. In vivo amyloid imaging with PET in frontotemporal dementia , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[120] Sid Gilman,et al. Positron emission tomography studies of cerebral glucose metabolism in chronic partial epilepsy , 1987, Annals of neurology.
[121] A. Convit,et al. Reduced hippocampal metabolism in MCI and AD , 2005, Neurology.
[122] D. Eidelberg. Positron emission tomography studies in parkinsonism. , 1992, Neurologic clinics.
[123] Sid Gilman,et al. Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography , 1988, Annals of neurology.
[124] Timo Grimmer,et al. Clinical severity of Alzheimer's disease is associated with PIB uptake in PET , 2009, Neurobiology of Aging.
[125] D. Eidelberg,et al. [11C]Raclopride‐PET studies of the Huntington's disease rate of progression: Relevance of the trinucleotide repeat length , 1998, Annals of neurology.
[126] A Drzezga,et al. Reduction of Benzodiazepine Receptor Binding is Related to the Seizure Onset Zone in Extratemporal Focal Cortical Dysplasia , 2000, Epilepsia.
[127] T Jones,et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. , 1990, Archives of neurology.
[128] J R Moeller,et al. The metabolic anatomy of Parkinson's disease: Complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies , 1990, Movement disorders : official journal of the Movement Disorder Society.
[129] J. Haxby,et al. Positron emission tomography in Alzheimer's disease , 1986, Neurology.
[130] J C Froment,et al. Positron Emission Tomography Metabolic Data Corrected for Cortical Atrophy Using Magnetic Resonance Imaging , 1996, Alzheimer disease and associated disorders.
[131] B. Maziére,et al. Positron emission tomography studies of brain receptors , 1991, Fundamental & clinical pharmacology.
[132] M. Hayden,et al. Positron emission tomography in the early diagnosis of Huntington's disease , 1986, Neurology.
[133] A. Drzezga,et al. Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET-study , 2007, Neurobiology of Aging.
[134] Michael J. Adam,et al. Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease , 1985, Nature.
[135] I. Savic,et al. Cortical Benzodiazepine Receptor Changes are Related to Frequency of Partial Seizures: A Positron Emission Tomography Study , 1996, Epilepsia.
[136] A. Alavi,et al. Fluorine-18-FDG evaluation of crossed cerebellar diaschisis in head injury. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[137] R. Hichwa,et al. PET scan investigations of Huntington's disease: Cerebral metabolic correlates of neurological features and functional decline , 1986, Annals of neurology.
[138] S. DeKosky,et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[139] O. Muzik,et al. Glucose and [11C]flumazenil positron emission tomography abnormalities of thalamic nuclei in temporal lobe epilepsy , 1999, Neurology.
[140] K Herholz,et al. Positron emission tomography imaging in dementia. , 2007, The British journal of radiology.
[141] V. Dhawan,et al. Changes in network activity with the progression of Parkinson's disease. , 2007, Brain : a journal of neurology.
[142] G. Small,et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[143] A. Alavi,et al. Predictors of outcome after anterior temporal lobectomy , 1994, Neurology.
[144] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[145] C. Nahmias,et al. Reduced striatal glucose consumption and prolonged reaction time are early features in Huntington's disease , 1984, Journal of the Neurological Sciences.
[146] C. DeCarli,et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. , 2007, Brain : a journal of neurology.
[147] T. Taniwaki,et al. Positron emission tomographic (PET) studies in dementia , 1993, Journal of the Neurological Sciences.
[148] A. Drzezga,et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[149] S. Gilman,et al. Patterns of cerebral glucose metabolism detected with positron emission tomography differ in multiple system atrophy and olivopontocerebellar atrophy , 1994, Annals of neurology.
[150] R. Hichwa,et al. Normal caudate glucose metabolism in persons at risk for Huntington??s disease , 1987 .
[151] S. DeKosky,et al. Binding of the Positron Emission Tomography Tracer Pittsburgh Compound-B Reflects the Amount of Amyloid-β in Alzheimer's Disease Brain But Not in Transgenic Mouse Brain , 2005, The Journal of Neuroscience.
[152] B. Miller,et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration , 2007, Neurology.
[153] R. Coleman,et al. Temporal lobe hypometabolism on PET , 1993, Neurology.
[154] J C Mazziotta,et al. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. , 1992, Archives of neurology.
[155] S. Sato,et al. Relation of EEG alpha background to parietal lobe function in Alzheimer's disease as measured by positron emission tomography and psychometry , 1988, Neurology.
[156] M. Richardson,et al. Benzodiazepine receptors in focal epilepsy with cortical dysgenesis: An 11C‐flumazenil PET study , 1996, Annals of neurology.
[157] A. Bol,et al. Positron tomography demonstrates frontal lobe hypometabolism in progressive supranuclear palsy , 1989, Annals of neurology.
[158] C D Marsden,et al. Differing patterns of striatal 18F‐dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy , 1990, Annals of neurology.
[159] N. Nakayama,et al. Focal brain glucose hypometabolism in patients with neuropsychologic deficits after diffuse axonal injury. , 2007, AJNR. American journal of neuroradiology.
[160] W. Jagust,et al. The diagnosis of Alzheimer-type dementia. A preliminary comparison of positron emission tomography and proton magnetic resonance. , 1984, JAMA.
[161] G. Alexander,et al. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. , 2002, The American journal of psychiatry.
[162] J. Mann,et al. Voxel-Based Analysis of 11C-PIB Scans for Diagnosing Alzheimer's Disease , 2008, Journal of Nuclear Medicine.
[163] A J Lees,et al. Steele-Richardson-Olszewski syndrome. Brain energy metabolism, blood flow and fluorodopa uptake measured by positron emission tomography. , 1988, Brain : a journal of neurology.
[164] G. Fein,et al. Presurgical multimodality neuroimaging in electroencephalographic lateralized temporal lobe epilepsy , 1997, Annals of neurology.
[165] B Horwitz,et al. Abnormal brain glucose metabolism in Alzheimer's disease, as measured by position emission tomography. , 1991, Advances in experimental medicine and biology.
[166] M. Mintun,et al. Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve. , 2008, Archives of neurology.
[167] P. Scheltens,et al. Advances in the early detection of Alzheimer's disease , 2004, Nature Reviews Neuroscience.
[168] R. Kessler,et al. Postsurgical outcome of patients with uncontrolled complex partial seizures and temporal lobe hypometabolism on 18FDG-positron emission tomography. , 1996, Investigative radiology.
[169] Olli Eskola,et al. [18F]FDOPA and [18F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease , 2001 .
[170] W. J. Brown,et al. Pathological findings underlying focal temporal lobe hypometabolism in partial epilepsy , 1982, Annals of neurology.
[171] M E Phelps,et al. Cerebral hyperglycolysis following severe traumatic brain injury in humans: a positron emission tomography study. , 1997, Journal of neurosurgery.
[172] A. Alavi,et al. 18F-2-deoxy-2-fluoro-D-glucose as a tracer in the positron emission tomographic study of senile dementia. , 1982, The American journal of psychiatry.
[173] J B Poline,et al. Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. , 2007, Brain : a journal of neurology.
[174] V. Sossi,et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease , 2000, Annals of neurology.
[175] T Jones,et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. , 1986, Journal of neurology, neurosurgery, and psychiatry.
[176] P. Thompson,et al. PET of brain amyloid and tau in mild cognitive impairment. , 2006, The New England journal of medicine.
[177] C. Nahmias,et al. Central Dopaminergic Pathways in Hemiparkinsonism Examined by Positron Emission Tomography , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[178] M. Iyo,et al. Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: Compartment analysis for β‐CFT binding with positron emission tomography , 1999, Annals of neurology.
[179] H. Lüders,et al. Outcome of temporal lobe epilepsy surgery predicted by statistical parametric PET imaging. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[180] C. Jack,et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.
[181] D. Selkoe,et al. Clinically diagnosed Alzheimer's disease: Autopsy results in 150 cases , 1988, Annals of neurology.
[182] W D Heiss,et al. STN-DBS activates the target area in Parkinson disease , 2008, Neurology.
[183] D A Shewmon,et al. Ictal Patterns of Cerebral Glucose Utilization in Children with Epilepsy , 1994, Epilepsia.
[184] G. Fink,et al. Positron emission tomography in the differential diagnosis of organic dementias. , 1991, Journal of neural transmission. Supplementum.
[185] J. Rinne,et al. Progression in Parkinson's disease: A positron emission tomography study with a dopamine transporter ligand [18F]CFT , 2000, Annals of neurology.
[186] J. Cummings,et al. Alzheimer's disease , 1998, Neurology.
[187] S. DeKosky,et al. Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[188] E. Reiman,et al. Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias , 2008, Journal of Nuclear Medicine.